Hemispherx Biopharma Inc. | |
Stock Exchange | NYSE |
EPS |
$9.43 |
Market Cap |
$9.02 M |
Shares Outstanding |
2.2 M |
Public Float |
47.63 M |
Hemispherx Biopharma Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
47.25 M |
Public Float |
46.11 M |
Address |
2117 South West Highway 484 Ocala Florida 32801 United States |
Employees | - |
Website | http://www.hemispherx.net |
Updated | 09/14/2018 |
Hemispherx Biopharma, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. |